0

524516

BACPHAR

img img img img
No Data Available

BACIL PHARMA LTD. Share Price Update

As of the latest trading session, BACIL PHARMA LTD. is trading at ₹55, down by ₹-1.02 or -1.82% from its previous close. The stock has moved between ₹53.26 and ₹57.00 today. Over the past year, the stock has delivered a return of 35.33%. In the last month, it has returned 15.21%.

Investment Returns

Over 1 Month 15.21% Over 3 Months 37.49% Over 6 Months 41.77% Over 1 Year 35.33%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

BACIL PHARMA LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 78.90
  • P/E Ratio (TTM) 109.86
  • Beta 0.45
  • Book Value / share 18.62
  • Return on equity -0.98%
  • EPS (TTM) 0.51
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 0.04
info icon alternate text

BACIL PHARMA LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.03
Net Profit 0.04
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.03
EBITDA 0.04
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.04
Net Profit 0.01
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.01
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.11
Net Profit 0.67
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.48
EBITDA 0.89
Effective Tax Rate (%) 24.71
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.07
Net Profit 0.02
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.03
EBITDA 0.02
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.06
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.00
Operating Expense 0.25
Net Profit 0.40
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.69
EBITDA 0.41
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 0.00
Operating Expense 0.19
Net Profit -0.06
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.10
EBITDA -0.06
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 0.00
Operating Expense 0.22
Net Profit -0.10
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.17
EBITDA -0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.00
Operating Expense 3.92
Net Profit -3.86
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -6.55
EBITDA -3.86
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 0.31
Net Profit -0.24
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -0.41
EBITDA -0.24
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.20
ROE % -0.98
ROCE % -1.04
Total Debt to Total Equity 0.01
EBITDA Margin 0.00
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.86
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.05
EBITDA Margin 0.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.68
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.02
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.08
EBITDA Margin 0.00
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2.13
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.13
EBITDA Margin 0.00
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.85
Total Assets 25.60
Total Liabilities 25.60
Total Equity 25.43
Share Outstanding 1
Price to Book Ratio 2.33
Return on Assets (%) 1.57
Return on Capital (%) 1.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 1.32
Total Liabilities 1.32
Total Equity 1.21
Share Outstanding 0
Price to Book Ratio 7.87
Return on Assets (%) -4.45
Return on Capital (%) -4.5
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 1.12
Total Liabilities 1.12
Total Equity 1.09
Share Outstanding 0
Price to Book Ratio 3.26
Return on Assets (%) -9.03
Return on Capital (%) -9.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.22
Total Assets 1.27
Total Liabilities 1.27
Total Equity 1.22
Share Outstanding 0
Price to Book Ratio 3.05
Return on Assets (%) -303.54
Return on Capital (%) -306.94
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 4.08
Total Liabilities 4.08
Total Equity 1.39
Share Outstanding 0
Price to Book Ratio 1.46
Return on Assets (%) -5.85
Return on Capital (%) -15.27
Particulars MAR 2025 (Values in Cr)
Net Income 0.40
Cash from Operations 0.40
Cash from Investing 0.33
Cash from Financing 2.07
Net change in Cash 2.81
Free Cash Flow 0.40
Particulars MAR 2024 (Values in Cr)
Net Income -0.05
Cash from Operations 0.00
Cash from Investing 0.07
Cash from Financing -0.06
Net change in Cash 0.01
Free Cash Flow 0.00
Particulars MAR 2023 (Values in Cr)
Net Income -0.10
Cash from Operations -0.14
Cash from Investing -0.11
Cash from Financing 0.06
Net change in Cash -0.20
Free Cash Flow -0.14
Particulars MAR 2022 (Values in Cr)
Net Income -3.86
Cash from Operations -4.00
Cash from Investing 3.81
Cash from Financing 0.32
Net change in Cash 0.13
Free Cash Flow -4.00
Particulars MAR 2021 (Values in Cr)
Net Income -0.23
Cash from Operations -0.39
Cash from Investing 0.52
Cash from Financing -0.07
Net change in Cash 0.05
Free Cash Flow -0.39
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 15.23 1.82 269.67 23.12 41.00
BLISS GVS PHARMA LTD 262.60 25.11 2.45 2778.02 105.05 277.80
CIPLA LTD 1294.75 22.00 3.17 104587.66 1165.55 1672.20
FERMENTA BIOTECH LIMITED 319.05 10.61 2.40 939.00 252.15 399.00
GLAXOSMITHKLINE PHARMA LT 2473.05 41.65 24.53 41894.96 2218.00 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.19 33.84 4.90 269.67 23.12 41.00
AMRUTANJAN HEALTH CARE LTD. 575.55 28.78 4.86 1663.95 490.00 789.95
ASTRAZENECA PHARMA IND LT 8501.75 102.17 26.60 21254.38 7630.00 10653.05
BLISS GVS PHARMA LTD 262.60 35.78 2.51 2778.02 105.05 277.80

BACIL PHARMA LTD. shareholding pattern

Holding
100.0%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

BACIL PHARMA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
55.00 -1.83 redarrow
red-green-graph indicator
7 Bearish
9 Bullish
  • 5 Days 57.40
  • 26 Days 54.10
  • 10 Days 56.80
  • 50 Days 50.80
  • 12 Days 56.50
  • 100 Days 46.90
  • 20 Days 55.10
  • 200 Days 43.00
56.99 PIVOT
First Support 55.07 First Resistance 57.94 Second Support 54.12 Second Resistance 59.86 Third Support 52.20 Third Resistance 60.81
RSI 55.54 ADX 21.51 MACD 2.43 Williams % R -55.11 Commodity Channel Index (CCI) 43.57
Date 2026-04-24 Week 2540.00 Same Day 1115.00 Month 11754.00
1 Year 0.45 3 Year 0.04
Over 1 Month
15.21% down
Over 1 Year
35.33% down
Over 3 Months
37.49% down
Over 3 Years
115.35% down
Over 6 Months
41.77% down
Over 5 Years
60.50% down

BACIL PHARMA LTD. Corporate Actions

Top Gainers

Top Losers

BACIL PHARMA LTD. Share Price

Incorporated as a private limited Company in Maharashtra in May, 1987, Bacil Pharma Limited (BPL) was converted into a Public limited company in October, 1988. The main business activity of the Company is Pharmaceutical.

Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Company's operations are based on focused approach.

Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Women's Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners.

Bal Pharma Unit - 1, is a finished dosage facility for manufacturing Tablets and Capsules. Bal Pharma Unit - 2, is involved in the manufacturing of APIs. A well-equipped R&D laboratory, a good Kilo laboratory and quality control facilities form the other spheres of activity here. Bal Pharma Unit - 3, is a finished dosage facility for manufacturing Intravenous Fluids, Ophthalmic Preparations & Liquid Oral Preparations.

BPL came out with a public issue of Rs 7 cr in Mar.'94 to set up a plant at Vapi to manufacture bulk drugs like atenalol, norfloxacin, pefloxacin and ciprofloxacin.

The company entered into a marketing arrangement with a distributor Kam Han Industries, Hong Kong, to export 50% of the production. Due to various reasons, the civil works at Vapi were affected. However, to avoid further delay in project implementation, the company acquired from SICOM an existing bulk drug unit with necessary infrastructure and production facilities at Lote Parashuram (near Ratnagiri).

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bacil Pharma Ltd?

Answer Field

Bacil Pharma Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 55.00 as on Apr 27 2026 03:30 PM.

What is the Market Cap of Bacil Pharma Ltd Share?

Answer Field

The market cap of Bacil Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 78.90 as on Apr 27 2026 03:30 PM.

What is the 52 Week High and Low of Bacil Pharma Ltd?

Answer Field

The 52 Week High and Low of Bacil Pharma Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 61.80 and ₹ 26.69.

What is 1 year return for Bacil Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 35.33%.

What is the P/E Ratio of Bacil Pharma Ltd Share?

Answer Field

As on Apr 27 2026 03:30 PM the price-to-earnings (PE) ratio for Bacil Pharma Ltd share is 109.86.

What is the PB ratio of Bacil Pharma Ltd Share?

Answer Field

As on Apr 27 2026 03:30 PM, the price-to-book (PB) ratio for Bacil Pharma Ltd share is 18.62.

How to Buy Bacil Pharma Ltd Share?

Answer Field

You can trade in Bacil Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bacil Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Bacil Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bacil Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|